Orexigen Therapeutics Inc

Orexigen Therapeutics — Investor Presentation (September 2012)

31 slides from Orexigen Therapeutics's investor presentation, Sep 5, 2012

  1. Slide 1: September 2012

    Exhibit 99.1 September 2012

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed,“ “probability” an

  3. Slide 3: Path to Commercial Success: Contrave Poised to Deliver

    Path to Commercial Success Orexigen: Contrave ® Poised to Deliver Path to approval Large, growing market Unmet need, limited competition Differentiated product profile Skilled partner with heavy resourcing Path to Commercial Success Orexigen: Contrave ® Poised to Deliver Regulatory clarity on the Li

  4. Slide 4: Path to Approval

    Path to Approval Path to Approval

  5. Slide 5: The Light Study was designed to satisfy the single approval deficiency identified in the CRL

    The Light Study was designed to satisfy the single approval deficiency identified in the CRL CRL identified a single approval deficiency of theoretical CV risk Complete NDA already reviewed by FDA – Efficacy threshold has been met – General safety & tolerability profile established – Positive Ad-Com

  6. Slide 6: The Light Study began enrolling patients June 2012

    The Light Study began enrolling patients June 2012 Protocol based on guidance from OND and conducted under a SPA Contrave could be approved with a positive interim analysis at 87 MACE events – Must exclude a doubling of MACE at the interim analysis to be approved – Must exclude a 40% increase at the

  7. Slide 7: Light Study Design

    Light Study Design Primary endpoint is ITT analysis of MACE (MI, stroke, CV death) Targeting MACE event rate of 1.5% per year Streamlined study - large sample size, but limited information per subject Contrave32 + WeightMate Placebo + WeightMate Wk 208 Wk 182 Wk 130 Wk 104 Wk 78 Wk 52 Wk 26 Wk 16 Wk

  8. Slide 8: Probability of Technical Success of the Light Study is High

    Probability of Technical Success of the Light Study is High Hurdle for approval requires excluding a doubling of CV risk in non- inferiority design, not demonstrating CV benefit Bupropion well characterized in >50M patients over >25 years – Large patient registries and AERS have not identified evide

  9. Slide 9: Our Focus is on Responders to Contrave Therapy

    Our Focus is on Responders to Contrave Therapy Illustrative : Typical distribution of weight loss response to obesity therapy Our Focus: Responders Non-responders discontinue drug therapy -10 -20 -30 -40

  10. Slide 10: Responders Maintained Meaningful Weight Loss

    Responders Maintained Meaningful Weight Loss Contrave Responders Achieved Significant Weight Loss Represents one year data for responders (patients with 5% weight loss at week per recommended treatment protocol) In the Contrave ® clinical development program the most frequent treatment-emergent adve

  11. Slide 11: Contrave Responders Achieve Improvements Across Multiple Cardiometabolic Parameters

    Contrave Responders Achieve Improvements Across Multiple Cardiometabolic Parameters Responders Maintained Meaningful Weight Loss Contrave32 Standardized Mean Change from Baseline at 1 Year Change from Baseline at 1 Year Contrave Responder N=1038 Proportion w/ 5% Wt Loss Wk 16 Contrave Responders Ach

  12. Slide 12: Risk Engine Modeling Suggests Long-term CVD Risk Reduction on Contrave

    Risk Engine Modeling Suggests Long-term CVD Risk Reduction on Contrave Risk Engine Modeling Suggests Long-term CVD Risk Reduction on Contrave

  13. Slide 13: Patient demographic targets are based on epidemiologic modeling and clinical trial experience

    Patient demographic targets are based on epidemiologic modeling and clinical trial experience Target Current (August) Patient demographic targets are based on epidemiologic modeling and clinical trial experience Age Younger Age Group <25% 14% Gender 50:50 (M:F) 44:56 Minority 15% >20% CV disease 30%

  14. Slide 14: Precise timing of the 87th event dependent on the actual observed event rate

    Precise timing of the 87 th event dependent on the actual observed event rate Precise timing of the 87 th event dependent on the actual observed event rate th event 3Q 12 4Q 12 1Q 13 2Q 13 3Q 13 4Q 13 1Q 14 2Q 14 Timing of 87 th event based on 1.5% event rate 2% 1.25% Interim analysis triggered by o

  15. Slide 15: Path to Commercial Success

    Path to Commercial Success Path to Commercial Success

  16. Slide 16: Contrave Poised for Commercial Success

    Contrave Poised for Commercial Success Market Size / Market Growth Unmet Need / Limited Competition Differentiated Product Profile Heavy Resourcing Contrave Poised for Commercial Success Blockbuster Building Blocks Blockbuster Building Blocks

  17. Slide 17: Obesity: A Large Untapped Market in Need of Solutions

    Obesity: A Large Untapped Market in Need of Solutions ~ 1 in 3 People in the US are Obese The obesity epidemic is also expected to grow globally n= ~ 685M people n= ~ 484M people Blockbuster Market Size Blockbuster Market Growth Obesity: A Large Untapped Market in Need of Solutions US Population Sou

  18. Slide 18: Significant Unmet Need in the Market

    Significant Unmet Need in the Market Treatment Options Needed Significant Unmet Need in the Market T2DM, 61% of which is attributable to obesity, is an epidemic 1 in 3 adults in the U.S. may have diabetes by 2050 (CDC) Associated with premature death & physical/psychosocial consequences Weight loss

  19. Slide 19: Contrave is Uniquely Positioned for Significant Segments of the Obese Population

    Contrave is Uniquely Positioned for Significant Segments of the Obese Population Has diabetes and/or dyslipidemia 62 % Has difficulty controlling eating in response to food cravings 50 % Is depressed or has depressive symptoms 63 % Is female, many of child bearing age 72 % Contrave is Uniquely Posit

  20. Slide 20: Patients With Diabetes On Contrave Achieve Improvements In Glycemic Control with Weight Loss

    Patients With Diabetes On Contrave Achieve Improvements In Glycemic Control with Weight Loss Patients With Diabetes On Contrave Achieve Improvements In Glycemic Control with Weight Loss As little as 5 - 10% weight loss has been shown to reduce mortality risk by ~25% Half the Contrave patients who co

  21. Slide 21: Patients with Dyslipidemia Experienced Clinically Significant Improvement in Lipid Profiles

    Patients with Dyslipidemia Experienced Clinically Significant Improvement in Lipid Profiles N=87 N=135 N=121 N=184 HDL Cholesterol Triglycerides Patients with Dyslipidemia Experienced Clinically Significant Improvement in Lipid Profiles Placebo P < 0.05 P < 0.05 P < 0.05 P < 0.05 Data is for complet

  22. Slide 22: GEN

    & GEN 1-402 11-409

  23. Slide 23: Patients Experienced Statistically Significant Improvements in Eating Control

    Patients Experienced Statistically Significant Improvements in Eating Control Patients Experienced Statistically Significant Improvements in Eating Control -20 -15 -10 -5 * * * Change from baseline (mm) -20 -15 -10 -5 * * * Change from baseline (mm) Less More Placebo (N=511) Contrave32 (N=471) How d

  24. Slide 24: Depressed Patients Experienced Significant Weight Loss and Improvements in Depressive Symptoms

    Depressed Patients Experienced Significant Weight Loss and Improvements in Depressive Symptoms Depressed Patients Experienced Significant Weight Loss and Improvements in Depressive Symptoms In a 24-week Phase 2 open-label trial of obese depressed patients, Contrave significantly improved measures of

  25. Slide 25: Contrave May Be The Logical Treatment Choice for Women

    Contrave May Be The Logical Treatment Choice for Women Contrave May Be The Logical Treatment Choice for Women Source: Orexigen market research; IMS Health, National Disease and Therapeutic Index, Obesity (2010) 18: 347-353 Women seek obesity therapy more than men Women tend to crave food more than m

  26. Slide 26: Empatic is Following Behind Contrave Providing a Different Tool for the Treatment of Obesity

    Empatic™ is Following Behind Contrave Providing a Different Tool for the Treatment of Obesity Empatic™ is Following Behind Contrave Providing a Different Tool for the Treatment of Obesity Empatic™ (zonisamide SR / bupropion SR) works by stimulating POMC and inhibiting AGRP/NPY – Enhances 5HT and DA

  27. Slide 27: Empatic Demonstrates Early and Progressive Weight Loss

    Empatic Demonstrates Early and Progressive Weight Loss Empatic Demonstrates Early and Progressive Weight Loss The most frequently reported adverse events in patients treated with Empatic were headache, insomnia, nausea and constipation. The most common reasons for discontinuation from treatment were

  28. Slide 28: In a Phase IIa Empatic clinical trial, completers demonstrated 15% weight loss at one year

    In a Phase IIa Empatic clinical trial, completers demonstrated 15% weight loss at one year In a Phase IIa Empatic clinical trial, completers demonstrated 15% weight loss at one year Completers Modified ITT-LOCF Week LS mean ± SE ZB-201 through Week 48 Placebo (N=72 through Week 24) ZB360 (N=66 throu

  29. Slide 29: Commercialization plans

    Commercialization plans Commercialization plans North American Contrave rights $50mm upfront to Orexigen $1 billion milestones including $100mm before first sale Tiered royalties on net sales from 20 – 35% Takeda has multi-year contractual promotional requirements Orexigen retains a right to co- pro

  30. Slide 30: Attractive Value Proposition for Orexigen

    Attractive Value Proposition for Orexigen Attractive Value Proposition for Orexigen Significant revenue potential projected from lead product, Contrave Retained ROW rights for future catalysts and upside Sufficient cash (~$126.2m as of June 30, 2012) to fund operations through Contrave NDA resubmiss

  31. Slide 31: Orexigen

    ts OREXIGEN

Orexigen Therapeutics — Investor Presentation (September 2012) on 6ix